Investor Presentaiton
MAT2Ai Combination Strategy
IDE397 (MAT2A) + AMG 193 (PRMT5MTA) Preclinical Efficacy
IDE397 (MAT2Ai) + AMG 193 (PRMT5MTA¡)
Tumor Volume (mm³)
Observed Durable Complete Responses
NSCLC MTAP-/- CDX Model
On Treatment
2000
1500-
1000-
500
Dosing (PO)
Vehicle
AMG 193 10 mg/kg
AMG 193 30 mg/kg
IDE397 3 mg/kg
AMG 193 10 mg/kg + IDE397 3 mg/kg
AMG 193 30 mg/kg + IDE397 3 mg/kg
Off Treatment
T TT
T
TT
10 20 30 40 50 60
70 80
90
Complete Response
Complete Response
100 110
Days (post cell implantation)
AMGEN®
Observed Complete Responses (CR) @ Study Day ~40+ durable
through Study Day ~100
Doses were below maximally efficacious preclinical dose for each of
IDE397 and AMG 193, with IDE397 dosed at 3 mg/kg QD (1/10th of
typical preclinical dose) → Therapeutic Window
Well tolerated in vivo with No Observed Body Weight Loss
Observed selective sensitivity in MTAP-null tumors (no observed TGI
in MTAP-wt tumors)
% Initial Body Weight
120-
100-
80-
80
60-
40-
20
No Body Weight Loss
0
0
5
10 15 20 25 30
35
Dosing (PO)
דן
40
27
IDEAYA / Amgen Data: AACR 2023, M. Fischer et al.
Days (post cell implantation)
* Pursuant to Amgen Clinical Trial Collaboration and Supply Agreement for clinical evaluation of IDE397 and AMG 193, an Amgen investigational MTA-cooperative PRMT5 inhibitor;
Amgen will sponsor the study; IDEAYA and Amgen will jointly share external costs of the study
IDEAVA
BIOSCIENCESView entire presentation